Head-to-head · WeighScore
Livea vs Zealthy
The verdict
Livea takes it — 69.7/100 to 46.7/100.
Livea grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Livea is a physician-supervised medical weight loss clinic founded in 2011 with 8 clinics in MN and WI, plus telehealth in MN, WI, Iowa, and Florida.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Livea | Zealthy |
|---|---|---|
| WeighScore | 69.7/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #120 | #496 |
| Semaglutide | $99/mo (plus a separate fee, compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $199/mo (compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | 4 states | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #120 · C
Strengths
- LegitScript certified; physician-owned Livea Medical PLLC; Medical Director Dr. Paul Olson, internal medicine/nephrology, 40 years experience
- Compounded sema from $99/mo and tirz from $199/mo — significantly cheaper than brand Ozempic/Wegovy ($1,000+/mo self-pay)
- Comprehensive program: InBody scans, registered dietitian nutrition counseling, health coaching, and regular provider check-ins included
- 15+ years established (founded 2011); 50,000+ clients served; voted Minnesota's Best Weight Loss Program 5 consecutive years
- Medications shipped to door; same-day consultations; in-person or telehealth; typically HSA/FSA eligible
Where it loses points
- Telehealth limited to 4 states only (MN, WI, IA, FL) — unavailable to most of the US; primarily a regional clinic network
- Pricing ambiguous: $69/mo program fee plus separate medication cost ($99/mo sema) may bring GLP-1 total to ~$168/mo
- Compounded tirzepatide availability uncertain — FDA announced shortage end in 2026; access subject to eligibility
- Labs (bloodwork) not explicitly included in any published program tier; confirmed at consultation only
- Strong MN/WI clinic focus; telehealth reach into IA and FL is newer and less established than core markets
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.